$404 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 38 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CEMI | Exit | CHEMBIO DIAGNOSTICS INC | $0 | – | -41,667 | -100.0% | -0.18% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -400,000 | -100.0% | -0.21% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -140,000 | -100.0% | -0.81% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -36,000 | -100.0% | -0.88% | – |
| MRUS | Exit | MERUS N V | $0 | – | -69,274 | -100.0% | -0.89% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -131,500 | -100.0% | -0.93% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -55,000 | -100.0% | -0.94% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -17,000 | -100.0% | -0.96% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -100,000 | -100.0% | -1.09% | – |
| IRIX | Exit | IRIDEX CORP | $0 | – | -1,171,300 | -100.0% | -1.56% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -22,500 | -100.0% | -1.85% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -112,500 | -100.0% | -1.95% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -418,500 | -100.0% | -3.63% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -134,000 | -100.0% | -3.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.